Over 90% of chronic pain (CP) patients receive opioids-based treatments, which led to a public health crisis with lasting impacts on social and economic wellbeing based on opioid addiction. Opioids act through activation of μ (MOR), δ (DOR), and κ (KOR) opioid receptors, which are broadly and differentially distributed throughout the brain. Chronic opioid consumption leads to brain changes such as alterations on neurotransmission, dendritic branching, and spine density, as well as an increase in apoptosis. To overcome opioid-related issues, extensive efforts have been made to search for an alternative treatment. Bioactive molecules secreted by stem cells, collectively known as secretome, have shown a positive impact in different pain models. However, there is a lack of studies on the role of secretome in modulating opioid receptors. By using cerebral organoids (CeO), a self-organized, functional, and multicellular 3D structure that resemble the brain, we were able to identify MOR, DOR, and KOR at different stages of maturation. Treatment with secretome increased MOR expression highlighting a possible role in pain signaling mechanisms. Opioid treatments did not impact the expression of neuronal maturation markers but together with secretome, they increased astrogliogenesis. Opioid-treated organoids presented higher dopamine secretion recapitulating an important physiological event after opioid exposure. This work demonstrates that CeO is an important model system for the study of opioid signaling with potential implications to the understanding of basic mechanisms related to pain physiology.
Get full access to this article
View all access options for this article.
References
1.
GuptaA, MayerEA, FlingC, LabusJS, NaliboffBD, HongJ-Y and KilpatrickLA. (2017). Sex-based differences in brain alterations across chronic pain conditions. J Neurosci Res, 95:604–616.
2.
Crofford LJ. (2015). Chronic pain: where the body meets the brain. Trans Am Clin Climatol Assoc, 126:167–183.
3.
Salsitz EA. (2016). Chronic pain, chronic opioid addiction: a complex nexus. J Med Toxicol, 12:54–57.
4.
CastonRM, SmithEH, DavisTS and RolstonJD. (2020). The cerebral localization of pain: anatomical and functional considerations for targeted electrical therapies. J Clin Med, 9:1945.
5.
BruehlS, ApkarianAV, BallantyneJC, BergerA, BorsookD, ChenWG, FarrarJT, HaythornthwaiteJA, HornSD, et al. (2013). Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges. J Pain, 14:103–113.
6.
DholakiyaSL, AlibertiA and BarileFA. (2016). Morphine sulfate concomitantly decreases neuronal differentiation and opioid receptor expression in mouse embryonic stem cells. Toxicol Lett, 247:45–55.
7.
ChavesC, RemiaoF, CisterninoS and DeclevesX. (2017). Opioids and the blood-brain barrier: a dynamic interaction with consequences on drug disposition in brain. Curr Neuropharmacol, 15:1156–1173.
8.
KochT and HölltV. (2008). Role of receptor internalization in opioid tolerance and dependence. Pharmacol Ther, 117:199–206.
9.
DacherM and NugentFS. (2011). Opiates and plasticity. Neuropharmacology, 61:1088–1096.
10.
Al-HasaniR and BruchasMR. (2011). Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology, 115:1363–1381.
11.
BediniA, BaiulaM and SpampinatoS. (2008). Transcriptional activation of human mu-opioid receptor gene by insulin-like growth factor-I in neuronal cells is modulated by the transcription factor REST. J Neurochem, 105:2166–2178.
12.
YangS and ChangMC. (2019). Chronic pain: structural and functional changes in brain structures and associated negative affective states. Int J Mol Sci, 20:3130.
13.
ApkarianVA, HashmiJA and BalikiMN. (2011). Pain and the brain: specificity and plasticity of the brain in clinical chronic pain. Pain, 152:S49–S64.
14.
NickelMM, MayES, TiemannL, SchmidtP, PostorinoM, Ta DinhS, GrossJ and PlonerM. (2017). Brain oscillations differentially encode noxious stimulus intensity and pain intensity. Neuroimage, 148:141–147.
15.
Ta DinhS, NickelMM, TiemannL, MayES, HeitmannH, HohnVD, EdenharterG, Utpadel-FischlerD, TölleTR, et al. (2019). Brain dysfunction in chronic pain patients assessed by resting-state electroencephalography. Pain, 160:2751–2765.
16.
TapocikJD, LuuTV, MayoCL, WangB-D, DoyleE, LeeAD, LeeNH and ElmerGI. (2013). Neuroplasticity, axonal guidance and micro-RNA genes are associated with morphine self-administration behavior. Addict Biol, 18:480–495.
17.
Beltrán-CamposV, Silva-VeraM, García-CamposML and Díaz-CintraS. (2015). Effects of morphine on brain plasticity. Neurologia (English Ed), 30:176–180.
18.
CaritisSN and PanigrahyA. (2019). Opioids affect the fetal brain: reframing the detoxification debate. Am J Obstet Gynecol, 221:602–608.
19.
Vilaça-FariaH, SalgadoAJ and TeixeiraFG. (2019). Mesenchymal stem cells-derived exosomes: a new possible therapeutic strategy for Parkinson's Disease?. Cells, 8:118.
20.
BriniAT, AmodeoG, FerreiraLM, MilaniA, NiadaS, MoschettiG, FranchiS, BorsaniE, RodellaLF, PaneraiAE and SacerdoteP. (2017). Therapeutic effect of human adipose-derived stem cells and their secretome in experimental diabetic pain. Sci Rep, 7:9904.
21.
GamaKB, SantosDS, EvangelistaAF, SilvaDN, De AlcântaraAC, Dos SantosRR, SoaresMBP and VillarrealCF. (2018). Conditioned medium of bone marrow-derived mesenchymal stromal cells as a therapeutic approach to neuropathic pain: a preclinical evaluation. Stem Cells Int, 2018:8179013.
22.
KhatabS, van OschG, KopsN, Bastiaansen-JenniskensY, BosP, VerhaarJ, BernsenM and van BuulG. (2018). Mesenchymal stem cell secretome reduces pain and prevents cartilage damage in a murine osteoarthritis model. Eur Cells Mater, 36:218–230.
23.
JuZ-H, LiangX, RenY-Y, ShuL-W, YanY-H and CuiX. (2021). Neurons derived from human-induced pluripotent stem cells express mu and kappa opioid receptors. Neural Regen Res, 16:653.
24.
BartfeldS and CleversH. (2017). Stem cell-derived organoids and their application for medical research and patient treatment. J Mol Med, 95:729–738.
25.
LancasterMA and HuchM. (2019). Disease modelling in human organoids. Dis Model Mech, 12:dmm039347.
26.
MaroteA, PomeshchikY, CollinA, GoldwurmS, LamasNJ, PintoL, SalgadoAJ and RoybonL. (2018). Generation of an induced pluripotent stem cell line (CSC-41) from a Parkinson's disease patient carrying a p.G2019S mutation in the LRRK2 gene. Stem Cell Res, 28:44–47.
27.
LancasterMA and KnoblichJA. (2014). Generation of cerebral organoids from human pluripotent stem cells. Nat Protoc, 9:2329–2340.
28.
LivakKJ and SchmittgenTD. (2001). Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods, 25:402–408.
29.
FengY, HeX, YangY, ChaoD, LazarusL H and XiaY. (2012). Current research on opioid receptor function. Curr Drug Targets, 13:230–246.
30.
MachelskaH and CelikMÖ. (2020). Opioid receptors in immune and glial cells—implications for pain control. Front Immunol, 11:300.
31.
YaoH, WuW, CerfI, ZhaoHW, WangJ, NegraesPD, MuotriAR and HaddadGG. (2020). Methadone interrupts neural growth and function in human cortical organoids. Stem Cell Res, 49:102065.
32.
AhmadAH and Abdul AzizCB. (2014). The brain in pain. Malays J Med Sci, 21:46–54.
33.
FerrerI, MartinezA, BoludaS, ParchiP and BarrachinaM. (2008). Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell Tissue Bank, 9:181–194.
34.
PertCB and SnyderSH. (1973). Opiate receptor: demonstration in nervous tissue. Science, 179:1011–1014.
35.
SimonEJ, HillerJM and EdelmanI. (1973). Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate. Proc Natl Acad Sci U S A, 70:1947–1949.
36.
TereniusL. (1973). Stereospecific interaction between narcotic analgesics and a synaptic plasm a membrane fraction of rat cerebral cortex. Acta Pharmacol Toxicol (Copenh), 32:317–320.
37.
Le MerrerJ, BeckerJAJ, BefortK and KiefferBL. (2009). Reward processing by the opioid system in the brain. Physiol Rev, 89:1379–1412.
38.
PengJ, SarkarS and ChangSL. (2012). Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. Drug Alcohol Depend, 124:223–228.
39.
ValentinoRJ and VolkowND. (2018). Untangling the complexity of opioid receptor function. Neuropsychopharmacology, 43:2514–2520.
40.
WangD, TawfikVL, CorderG, LowSA, FrançoisA, BasbaumAI and ScherrerG. (2018). Functional divergence of delta and mu opioid receptor organization in CNS pain circuits. Neuron, 98:90–108.e5.
41.
HauserKF and KnappPE. (2018). Opiate drugs with abuse liability hijack the endogenous opioid system to disrupt neuronal and glial maturation in the central nervous system. Front Pediatr, 5:294.
42.
ChenJ, LiangL, LiY, ZhangY, ZhangM, YangT, MengF, LaiX, LiC, et al. (2020). Naloxone regulates the differentiation of neural stem cells via a receptor-independent pathway. FASEB J, 34:5917–5930.
43.
KimE, ClarkAL, KissA, HahnJW, WesselschmidtR, CosciaCJ and BelchevaMM. (2006). μ- and κ-opioids induce the differentiation of embryonic stem cells to neural progenitors. J Biol Chem, 281:33749–33760.
44.
Stiene-MartinA, KnappPE, MartinK, GurwellJA, RyanS, ThorntonSR, SmithFL and HauserKF. (2001). Opioid system diversity in developing neurons, astroglia, and oligodendroglia in the subventricular zone and striatum: impact on gliogenesis in vivo. Glia, 36:78–88.
45.
TarachaE, MierzejewskiP, LehnerM, ChrapustaSJ, KałaM, LechowiczW, HamedA, SkórzewskaA, KostowskiW and PłaźnikA. (2009). Stress-opioid interactions: a comparison of morphine and methadone. Pharmacol Reports, 61:424–435.
46.
VienTN, GleasonCA, HaysSL, McPhersonRJ, ChavkinC and JuulSE. (2009). Effects of neonatal stress and morphine on kappa opioid receptor signaling. Neonatology, 96:235–243.
47.
GendronL, MittalN, BeaudryH and WalwynW. (2015). Recent advances on the δ opioid receptor: from trafficking to function. Br J Pharmacol, 172:403–419.
48.
CahillCM, MorinvilleA, LeeM-C, VincentJ-P, CollierB and BeaudetA. (2001). Prolonged morphine treatment targets δ opioid receptors to neuronal plasma membranes and enhances δ-mediated antinociception. J Neurosci, 21:7598–7607.
49.
PathanH and WilliamsJ. (2012). Basic opioid pharmacology: an update. Br J Pain, 6:11–16.
50.
MazákK, NoszálB and HosztafiS. (2019). Advances in the physicochemical profiling of opioid compounds of therapeutic interest. ChemistryOpen, 8:879–887.
51.
Van WageningenS, KemmerenP, LijnzaadP, MargaritisT, BenschopJJ, De CastroIJ, Van LeenenD, Groot KoerkampMJA, KoCW, et al (2010). Functional overlap and regulatory links shape genetic interactions between signaling pathways. Cell, 143:991–1004.
52.
VawdaR, BadnerA, HongJ, MikhailM, DragasR, XhimaK, JoseA and FehlingsMG. (2020). Harnessing the secretome of mesenchymal stromal cells for traumatic spinal cord injury: Multicell comparison and assessment of in vivo efficacy. Stem Cells Dev, 29:1429–1443.
53.
VrijsenKR, MaringJA, ChamuleauSAJ, VerhageV, MolEA, DeddensJC, MetzCHG, LodderK, van EeuwijkECM, et al (2016). Exosomes from cardiomyocyte progenitor cells and mesenchymal stem cells stimulate angiogenesis Via EMMPRIN. Adv Healthc Mater, 5:2555–2565.
54.
KrausJ, BörnerC, LendeckelU and HölltV. (2006). Interferon-γ down-regulates transcription of the μ-opioid receptor gene in neuronal and immune cells. J Neuroimmunol, 181:13–18.
55.
TekiehE, ZaringhalamJ, ManahejiH, MaghsoudiN, AlaniB and ZardoozH. (2011). Increased serum IL-6 level time-dependently regulates hyperalgesia and spinal mu opioid receptor expression during CFA-induced arthritis. EXCLI J, 10:23–33.
56.
SenD, HuchitalM and ChenYL. (2013). Crosstalk between delta opioid receptor and nerve growth factor signaling modulates neuroprotection and differentiation in rodent cell models. Int J Mol Sci, 14:21114–21139.
57.
ZaringhalamJ, HormoziA, TekiehE, RazaviJ, KhanmohammadR and GolabiS. (2014). Serum IL-10 involved in morphine tolerance development during adjuvant-induced arthritis. J Physiol Biochem, 70:497–507.
58.
LanteroA, TramullasM, Pilar-CuellarF, ValdizanE, SantillanR, RoquesBP and HurleMA. (2014). TGF- and opioid receptor signaling crosstalk results in improvement of endogenous and exogenous opioid analgesia under pathological pain conditions. J Neurosci, 34:5385–5395.
59.
Al-FadhelSZ, Al-HakeimHK, Al-DujailiAH and MaesM. (2019). IL-10 is associated with increased mu-opioid receptor levels in major depressive disorder. Eur Psychiatry, 57:46–51.
60.
MaierT, GüellM and SerranoL. (2009). Correlation of mRNA and protein in complex biological samples. FEBS Lett, 583:3966–3973.
61.
WethmarK, SminkJJ and LeutzA. (2010). Upstream open reading frames: Molecular switches in (patho)physiology. BioEssays, 32:885–893.
62.
BarrettLW, FletcherS and WiltonSD. (2012). Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. Cell Mol Life Sci, 69:3613–3634.
HaoJ, LiS, ShiX, QianZ, SunY, WangD, ZhouX, QuH, HuS, et al. (2018). Bone marrow mesenchymal stem cells protect against n-hexane-induced neuropathy through beclin 1-independent inhibition of autophagy. Sci Rep, 8:4516.
65.
ZhangX, KongY, SunY, QianZ, GaoC, ShiX, LiS, PiaoY and PiaoF. (2018). Bone marrow mesenchymal stem cells conditioned medium protects VSC4.1 cells against 2,5-hexanedione-induced autophagy via NGF-PI3K/Akt/mTOR signaling pathway. Brain Res, 1696:1–9.
66.
BajicD, CommonsKG and SorianoSG. (2013). Morphine-enhanced apoptosis in selective brain regions of neonatal rats. Int J Dev Neurosci, 31:258–266.
67.
SvenssonA-L, BuchtN, HallbergM and NybergF. (2008). Reversal of opiate-induced apoptosis by human recombinant growth hormone in murine foetus primary hippocampal neuronal cell cultures. Proc Natl Acad Sci USA, 105:7304–7308.
68.
KugawaF, Ueno A and MAoki. (2000). Apoptosis of NG108-15 cells induced by buprenorphine hydrochloride occurs via the caspase-3 pathway. Biol Pharm Bull, 23:930–935.
69.
Özden S and IsenmannS. (2004). Neuroprotective properties of different anesthetics on axotomized rat retinal ganglion cells in vivo. J Neurotrauma, 21:73–82.
70.
NaritaM, KuzumakiN, MiyatakeM, SatoF, WachiH, SeyamaY and SuzukiT. (2006). Role of delta-opioid receptor function in neurogenesis and neuroprotection. J Neurochem, 97:1494–1505.
71.
ChenYL, MonteithN, LawP-Y and LohHH. (2010). Dynamic association of p300 with the promoter of the G protein-coupled rat delta opioid receptor gene during NGF-induced neuronal differentiation. Biochem Biophys Res Commun, 396:294–298.
72.
Mendes-PinheiroB, TeixeiraFG, AnjoSI, ManadasB, BehieLA and SalgadoAJ. (2018). Secretome of undifferentiated neural progenitor cells induces histological and motor improvements in a rat model of Parkinson's Disease. Stem Cells Transl Med, 7:829–838.
73.
Baez-JuradoE, Hidalgo-LanussaO, Barrera-BailónB, SahebkarA, AshrafGM, EcheverriaV and BarretoGE. (2019). Secretome of mesenchymal stem cells and its potential protective effects on brain pathologies. Mol Neurobiol, 56:6902–6927.
74.
TeixeiraF and SalgadoA. (2020). Mesenchymal stem cells secretome: Current trends and future challenges. Neural Regen Res, 15:75–77.
75.
WoodCR, JuárezEH, FerriniF, MyintP, InnesJ, LossiL, MerighiA and JohnsonWEB. (2021). Mesenchymal stem cell conditioned medium increases glial reactivity and decreases neuronal survival in spinal cord slice cultures. Biochem Biophys Reports, 26:100976.
76.
SarkarP, RedondoJ, KempK, GintyM, WilkinsA, ScoldingNJ and RiceCM. (2018). Reduced neuroprotective potential of the mesenchymal stromal cell secretome with ex vivo expansion, age and progressive multiple sclerosis. Cytotherapy, 20:21–28.
77.
WillnerD, Cohen-YeshurunA, AvidanA, OzerskyV, ShohamiE and LekerRR. (2014). Short term morphine exposure in vitro alters proliferation and differentiation of neural progenitor cells and promotes apoptosis via Mu Receptors. PLoS One, 9:e103043.
78.
AltmanJ and DasGD. (1965). Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. J Comp Neurol, 124:319–335.
79.
KaplanM and HindsJ. (1977). Neurogenesis in the adult rat: electron microscopic analysis of light radioautographs. Science (80-), 197:1092–1094.
PathaniaM, YanLD and BordeyA. (2010). A symphony of signals conducts early and late stages of adult neurogenesis. Neuropharmacology, 58:865–876.
82.
ZhalehH, AzadbakhtM and Bidmeshki PourA. (2020). Low concentrations of morphine enhanced the neuroglia-like differentiation. Bratislava Med J, 121:271–277.
83.
TenconiB. (1996). High opioid doses inhibit whereas low doses enhance neuritogenesis in PC12 cells. Dev Brain Res, 94:175–181.
84.
ChangS-F and MokMS. (2001). The influence of different sub-type delta opioid receptors in nerve growth factor-induced neuronal differentiation in rat pheochromocytoma PC12 cell. Neurosci Lett, 314:29–32.
85.
NavratilovaE and PorrecaF. (2014). Reward and motivation in pain and pain relief. Nat Neurosci, 17:1304–1312.
86.
WiseRA and KoobGF. (2014). The development and maintenance of drug addiction. Neuropsychopharmacology, 39:254–262.
87.
KoobGF and VolkowND. (2016). Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry, 3:760–773.
88.
NobleF and MarieN. (2019). Management of opioid addiction with opioid substitution treatments: beyond methadone and buprenorphine. Front Psychiatry, 9:742.
89.
FujitaM, IdeS and IkedaK, (2019). Opioid and nondopamine reward circuitry and state-dependent mechanisms. Ann N Y Acad Sci, 1451:29–41.
90.
SeverinoAL, MittalN, HakimianJK, VelardeN, MinasyanA, AlbertR, TorresC, RomaneschiN, JohnstonC, et al. (2020). μ-Opioid receptors on distinct neuronal populations mediate different aspects of opioid reward-related behaviors. eNeuro, 7:ENEURO.0146-20.2020.
91.
CheferVI and ShippenbergTS. (2009). Augmentation of morphine-induced sensitization but reduction in morphine tolerance and reward in delta-opioid receptor knockout mice. Neuropsychopharmacology, 34:887–898.
92.
Le MerrerJ, Plaza-ZabalaA, Del BocaC, MatifasA, MaldonadoR and KiefferBL. (2011). Deletion of the δ opioid receptor gene impairs place conditioning but preserves morphine reinforcement. Biol Psychiatry, 69:700–703.
93.
EscobarA del P, CasanovaJP, AndrésME and FuentealbaJA. (2020). Crosstalk between kappa opioid and dopamine systems in compulsive behaviors. Front Pharmacol, 11:57.
94.
CrowleyNA and KashTL. (2015). Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment. Prog Neuropsychopharmacol Biol Psychiatry, 62:51–60.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
